Walgreens Boots Alliance (NASDAQ:WBA) will release its earnings data on Tuesday, April 3rd. Analysts expect Walgreens Boots Alliance to post earnings of $1.50 per share for the quarter. Walgreens Boots Alliance has set its FY18 guidance at $5.45-5.70 EPS.
Walgreens Boots Alliance (NASDAQ:WBA) last posted its quarterly earnings results on Thursday, January 4th. The pharmacy operator reported $1.28 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.01. The firm had revenue of $30.74 billion during the quarter, compared to the consensus estimate of $30.39 billion. Walgreens Boots Alliance had a return on equity of 19.15% and a net margin of 3.19%. The business’s revenue was up 7.9% compared to the same quarter last year. During the same period last year, the company earned $1.10 earnings per share. On average, analysts expect Walgreens Boots Alliance to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.
WBA stock opened at $67.47 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.96 and a quick ratio of 0.47. The firm has a market capitalization of $64,819.47, a P/E ratio of 18.64, a price-to-earnings-growth ratio of 1.08 and a beta of 1.21. Walgreens Boots Alliance has a one year low of $63.82 and a one year high of $87.79.
A number of research firms have weighed in on WBA. Pivotal Research decreased their price target on Walgreens Boots Alliance from $73.00 to $69.00 and set a “hold” rating for the company in a research note on Friday. Zacks Investment Research upgraded Walgreens Boots Alliance from a “hold” rating to a “buy” rating and set a $74.00 price target for the company in a research note on Thursday, March 22nd. TheStreet downgraded Walgreens Boots Alliance from a “b-” rating to a “c+” rating in a research note on Tuesday, March 20th. BidaskClub downgraded Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 22nd. Finally, Barclays began coverage on Walgreens Boots Alliance in a research note on Thursday, March 8th. They issued an “equal weight” rating and a $76.00 price target for the company. One analyst has rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Walgreens Boots Alliance currently has a consensus rating of “Buy” and a consensus price target of $84.45.
In other Walgreens Boots Alliance news, insider Stefano Pessina purchased 98,858 shares of the firm’s stock in a transaction dated Monday, January 15th. The shares were bought at an average price of $76.07 per share, for a total transaction of $7,520,128.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 14.80% of the stock is owned by company insiders.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.